Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Obstructive Lung Diseases

  Free Subscription

Articles published in Respir Med

Retrieve available abstracts of 175 articles:
HTML format

Single Articles

    November 2022
  1. ALIBERTI S, Gramegna A, Zucchetti S, Simonetta E, et al
    Respiratory viruses in stable bronchiectasis: A multicenter evaluation in Northern Italy.
    Respir Med. 2022;205:107056.

  2. SUNJAYA A, Poulos L, Reddel H, Jenkins C, et al
    Qualitative validation of the modified Medical Research Council (mMRC) dyspnoea scale as a patient-reported measure of breathlessness severity.
    Respir Med. 2022;203:106984.
    PubMed     Abstract available

  3. KOSTER TD, Eberhardt R, Huebner RH, Valipour A, et al
    A multicenter, prospective, single-arm clinical investigation of a modified staged treatment algorithm using the AeriSeal system - The STAGE trial.
    Respir Med. 2022;203:106989.
    PubMed     Abstract available

  4. GOGOU E, Hatzoglou C, Zarogiannis SG, Siachpazidou D, et al
    Are younger COPD patients adequately vaccinated for influenza and pneumococcus?
    Respir Med. 2022;203:106988.
    PubMed     Abstract available

    Corrected formula for rectangular area ratio (RAR), a parameter used to quantify airflow limitation on expiratory flow-volume curves.
    Respir Med. 2022;204:107032.
    PubMed     Abstract available

  6. MUKHERJEE P, Bhattacharya D, Esquinas AM, Mandal M, et al
    HFNC can bring the children with bronchiolitis off the ventilator earlier: Fact or fiction?
    Respir Med. 2022;204:107033.

  7. KAHNERT K, Jorres RA, Jobst B, Wielputz MO, et al
    Association of coronary artery calcification with clinical and physiological characteristics in patients with COPD: Results from COSYCONET.
    Respir Med. 2022;204:107014.
    PubMed     Abstract available

  8. SANSORES RH, Paulin-Prado P, Robles-Hernandez R, Montiel-Lopez F, et al
    Clinical and microbiological characteristics and inflammatory profile during an exacerbation of COPD due to biomass exposure. A comparison with COPD due to tobacco exposure.
    Respir Med. 2022;204:107010.
    PubMed     Abstract available

  9. MOCHIZUKI F, Tanabe N, Iijima H, Shimada T, et al
    Early chronic obstructive pulmonary disease: Associations of two spirometry criteria with clinical features.
    Respir Med. 2022;204:107011.
    PubMed     Abstract available

    October 2022
  10. MAIO S, Murgia N, Tagliaferro S, Angino A, et al
    The Italian severe/uncontrolled asthma registry (RItA): A 12-month clinical follow-up.
    Respir Med. 2022;205:107030.
    PubMed     Abstract available

  11. VAN DER PALEN J, Slade D, Rehal S, Verma M, et al
    A randomized, cross-over study comparing critical and overall errors, learning time, and preference of the ELLIPTA versus BREEZHALER dry powder inhalers in patients with asthma.
    Respir Med. 2022;205:107031.
    PubMed     Abstract available

  12. RYAN D, Keighley A, Jackson T
    Patient perspectives in asthma: Listening to and learning from a new paradigm in translational research.
    Respir Med. 2022;205:107013.

  13. CHAN KC, Au CT, Wong E, Chook P, et al
    Inferior endothelial function improved following optimisation of asthma control in children.
    Respir Med. 2022;204:107024.
    PubMed     Abstract available

  14. TOOBA R, Wu TD
    Obesity and asthma: A focused review.
    Respir Med. 2022;204:107012.

  15. CABALLERO-SEGURA FJ, Lopez-de-Andres A, Jimenez-Garcia R, de Miguel-Yanes JM, et al
    Trends in asthma hospitalizations among adults in Spain: Analysis of hospital discharge data from 2011 to 2020.
    Respir Med. 2022;204:107009.
    PubMed     Abstract available

  16. GHOSH S, Rihan M, Ahmed S, Pande AH, et al
    Immunomodulatory potential of apolipoproteins and their mimetic peptides in asthma: Current perspective.
    Respir Med. 2022;204:107007.
    PubMed     Abstract available

  17. PATRICIA DE SOUZA MENDES L, Parreira VF, Spencer LM, Zafiropoulos B, et al
    Glittre endurance test: A new test to assess the functional capacity of individuals with chronic obstructive pulmonary disease.
    Respir Med. 2022;202:106983.
    PubMed     Abstract available

  18. VITACCA M, Paneroni M, Spanevello A, Ceriana P, et al
    Effectiveness of pulmonary rehabilitation in individuals with Chronic Obstructive Pulmonary Disease according to inhaled therapy: The Maugeri study.
    Respir Med. 2022;202:106967.
    PubMed     Abstract available

  19. HINES SE, Gaitens JM, Brown CH, Glick DR, et al
    Self-reported respiratory outcomes associated with blast exposure in post 9/11 veterans.
    Respir Med. 2022;202:106963.
    PubMed     Abstract available

    September 2022
  20. MANEECHOTESUWAN K, Singh D, Fritscher LG, Dursunoglu N, et al
    Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis.
    Respir Med. 2022;203:106993.
    PubMed     Abstract available

  21. TRAN C, Singh GV, Haider E, Boylan C, et al
    Luminal mucus plugs are spatially associated with airway wall thickening in severe COPD and asthma: A single-centered, retrospective, observational study.
    Respir Med. 2022;202:106982.
    PubMed     Abstract available

  22. ROCHE N, Aggarwal B, Boucot I, Mittal L, et al
    The impact of inhaler technique on clinical outcomes in adolescents and adults with asthma: A systematic review.
    Respir Med. 2022;202:106949.
    PubMed     Abstract available

  23. SUNJAYA AP, Sengupta A, Martin A, Di Tanna GL, et al
    Efficacy of self-management mobile applications for patients with breathlessness: Systematic review and quality assessment of publicly available applications.
    Respir Med. 2022;201:106947.
    PubMed     Abstract available

  24. ODAJIU I, Covantsev S, Sivapalan P, Mathioudakis AG, et al
    Peripheral neuropathy: A neglected cause of disability in COPD - A narrative review.
    Respir Med. 2022;201:106952.
    PubMed     Abstract available

  25. CHRISTENSEN VL, Rustoen T, Thoresen M, Holm AM, et al
    Stability of distinct symptom experiences in patients with chronic obstructive pulmonary disease (COPD).
    Respir Med. 2022;201:106944.
    PubMed     Abstract available

  26. AMIN R, Maiya GA, Mohapatra AK, Acharya V, et al
    Effect of a home-based pulmonary rehabilitation program on functional capacity and health-related quality of life in people with interstitial lung disease - A randomized controlled trial protocol.
    Respir Med. 2022;201:106927.
    PubMed     Abstract available

  27. CHOI J, Park E, Park H, Kang D, et al
    Effect of high-flow nasal cannula on mechanical ventilator duration in bronchiolitis patients.
    Respir Med. 2022;201:106946.
    PubMed     Abstract available

  28. FINAMORE P, Lattanzi G, Pedone C, Poci S, et al
    Energy expenditure and intake in COPD: The extent of unnoticed unbalance by predicting REE.
    Respir Med. 2022;201:106951.
    PubMed     Abstract available

  29. DIERICK BJH, Been-Buck S, Klemmeier T, Hagedoorn P, et al
    Digital spacer data driven COPD inhaler adherence education: The OUTERSPACE proof-of-concept study.
    Respir Med. 2022;201:106940.
    PubMed     Abstract available

  30. SOUTO-MIRANDA S, Vaes AW, Gloeckl R, Grongstad A, et al
    International perspectives on outcome measurement in pulmonary rehabilitation of people with COPD: A qualitative study.
    Respir Med. 2022;201:106936.
    PubMed     Abstract available

  31. HAMAKAWA Y, Sato S, Tanabe N, Rhee CK, et al
    Non-respiratory symptom dominance is associated with depression in patients with chronic obstructive pulmonary disease.
    Respir Med. 2022;201:106895.
    PubMed     Abstract available

    August 2022
  32. DOLLIVER WR, Wang W, Nardelli P, Rahaghi FN, et al
    Pulmonary arterial pruning is associated with CT-derived bronchiectasis progression in smokers.
    Respir Med. 2022;202:106971.
    PubMed     Abstract available

  33. BOURDIN A, Virchow JC, Papi A, Lugogo NL, et al
    Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
    Respir Med. 2022;202:106938.
    PubMed     Abstract available

  34. TAJIRI S, Kondo T, Tanigaki T, Hibino M, et al
    Daily inhaled flow profiles and drug release from dry powder inhalers in patients with bronchial asthma.
    Respir Med. 2022;201:106950.
    PubMed     Abstract available

  35. CHAPMAN KR, Canonica GW, Lavoie KL, Nenasheva N, et al
    Patients' and physicians' perspectives on the burden and management of asthma: Results from the APPaRENT 2 study.
    Respir Med. 2022;201:106948.
    PubMed     Abstract available

  36. CANONICA GW, Spanevello A, de Llano LP, Domingo Ribas C, et al
    Is asthma control more than just an absence of symptoms? An expert consensus statement.
    Respir Med. 2022;202:106942.
    PubMed     Abstract available

  37. SOUTO-MIRANDA S, Antao J, Rodrigues G, Mendes MA, et al
    Cut-off of the one-minute sit-to-stand test to detect functional impairment in people with chronic obstructive pulmonary disease.
    Respir Med. 2022;199:106892.
    PubMed     Abstract available

  38. TRELA KC, Zajac P, Zhu M, Press VG, et al
    Health literacy and type of education intervention predicting post-education metered-dose inhaler misuse.
    Respir Med. 2022;200:106930.
    PubMed     Abstract available

  39. FRAZIER WD, DaVanzo JE, Dobson A, Heath S, et al
    Early Initiation of non-invasive ventilation at home improves survival and reduces healthcare costs in COPD patients with chronic hypercapnic respiratory failure: A retrospective cohort study.
    Respir Med. 2022;200:106920.
    PubMed     Abstract available

  40. MALTAIS F, Vogelmeier CF, Kerwin EM, Bjermer LH, et al
    Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD.
    Respir Med. 2022;200:106918.
    PubMed     Abstract available

    July 2022
  41. HINE C, Desai M, Davies J, Sapey E, et al
    A systematic review of lung clearance index in non-cystic fibrosis, non-primary ciliary dyskinesia bronchiectasis.
    Respir Med. 2022;201:106937.
    PubMed     Abstract available

  42. ORLOVIC M, Magni T, Lukyanov V, Guerra I, et al
    Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England.
    Respir Med. 2022;201:106934.
    PubMed     Abstract available

  43. LI M, Wen Ma Z, Jun Deng S, Oliver BG, et al
    Development and validation of a noninvasive prediction model for identifying eosinophilic asthma.
    Respir Med. 2022;201:106935.
    PubMed     Abstract available

  44. HENRY SL, Moore LE, Brotto AR, Rowland S, et al
    Systemic vascular health is compromised in both confirmed and unconfirmed asthma.
    Respir Med. 2022;200:106932.
    PubMed     Abstract available

  45. ALHABEEB FF, Whitmore GA, Vandemheen KL, FitzGerald JM, et al
    Disease burden in individuals with symptomatic undiagnosed asthma or COPD.
    Respir Med. 2022;200:106917.
    PubMed     Abstract available

  46. DALIN DA, Lokke A, Kristiansen P, Jensen C, et al
    A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD.
    Respir Med. 2022;198:106880.
    PubMed     Abstract available

  47. YOHANNES AM, Murri MB, Hanania NA, Regan EA, et al
    Depressive and anxiety symptoms in patients with COPD: A network analysis.
    Respir Med. 2022;198:106865.
    PubMed     Abstract available

  48. AL CHIKHANIE Y, Bailly S, Amroussa I, Veale D, et al
    Clustering of COPD patients and their response to pulmonary rehabilitation.
    Respir Med. 2022;198:106861.
    PubMed     Abstract available

  49. ZAFARI Z, Lee TY, Sadatsafavi M
    External validation of lung function predictions in real-world cohorts of COPD.
    Respir Med. 2022;198:106859.
    PubMed     Abstract available

    June 2022
  50. PATELLA V, Pelaia C, Zunno R, Pelaia G, et al
    Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic.
    Respir Med. 2022;200:106916.
    PubMed     Abstract available

  51. LIU L, Zhang X, Zhang L, Liu Y, et al
    Reduced bronchodilator reversibility correlates with non-type 2 high asthma and future exacerbations: A prospective cohort study.
    Respir Med. 2022;200:106924.
    PubMed     Abstract available

  52. HUGHES R, Rapsomaniki E, Janson C, Keen C, et al
    Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study.
    Respir Med. 2022;200:106921.
    PubMed     Abstract available

  53. CAZZOLA M, Braido F, Calzetta L, Matera MG, et al
    The 5T approach in asthma: Triple Therapy Targeting Treatable Traits.
    Respir Med. 2022;200:106915.
    PubMed     Abstract available

  54. LUOTO J, Pihlsgard M, Pistolesi M, Paoletti M, et al
    Emphysema severity index (ESI) associated with respiratory death in a large Swedish general population.
    Respir Med. 2022;200:106899.
    PubMed     Abstract available

  55. LEONARD SI, Turi ER, Powell JS, Usseglio J, et al
    Associations of asthma self-management and mental health in adolescents: A scoping review.
    Respir Med. 2022;200:106897.
    PubMed     Abstract available

  56. SINGH D, Rabe KF, Martinez FJ, Krull M, et al
    Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary d
    Respir Med. 2022;197:106857.
    PubMed     Abstract available

  57. BRUSSE-KEIZER M, Citgez E, Zuur-Telgen M, Kerstjens HAM, et al
    Difference in survival between COPD patients with an impaired immune reaction versus an adequate immune reaction to seasonal influenza vaccination: The COMIC study.
    Respir Med. 2022;197:106851.
    PubMed     Abstract available

  58. SULKU J, Janson C, Melhus H, Stallberg B, et al
    Changes in critical inhaler technique errors in inhaled COPD treatment - A one-year follow-up study in Sweden.
    Respir Med. 2022;197:106849.
    PubMed     Abstract available

  59. COLAK Y, Nordestgaard BG, Vestbo J, Afzal S, et al
    Potential clinical implications of targeted spirometry for detection of COPD: A contemporary population-based cohort study.
    Respir Med. 2022;197:106852.
    PubMed     Abstract available

  60. DA LUZ GOULART C, Oliveira MR, Sendin FA, Mendes RG, et al
    Prognostic value of key variables from cardiopulmonary exercise testing in patients with COPD: 42-month follow-up.
    Respir Med. 2022;197:106856.
    PubMed     Abstract available

  61. MANNINO D, Bogart M, Wu B, Germain G, et al
    Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
    Respir Med. 2022;197:106807.
    PubMed     Abstract available

  62. YOHANNES AM, Casaburi R, Dryden S, Hanania NA, et al
    The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety.
    Respir Med. 2022;197:106850.
    PubMed     Abstract available

    May 2022
  63. SON JH, Park JS, Lee JU, Kim MK, et al
    A genome-wide association study on frequent exacerbation of asthma depending on smoking status.
    Respir Med. 2022 May 17:106877. doi: 10.1016/j.rmed.2022.106877.
    PubMed     Abstract available

  64. IKWU I, Nicolas LG, Mehari A, Gillum RF, et al
    Fractional exhaled nitric oxide and mortality in asthma and chronic obstructive pulmonary disease in a national cohort aged 40 years and older.
    Respir Med. 2022 May 16:106879. doi: 10.1016/j.rmed.2022.106879.
    PubMed     Abstract available

  65. JIAO T, Schnitzer ME, Forget A, Blais L, et al
    Identifying asthma patients at high risk of exacerbation in a routine visit: A machine learning model.
    Respir Med. 2022;198:106866.
    PubMed     Abstract available

  66. GOLAM SM, Janson C, Beasley R, FitzGerald JM, et al
    The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study.
    Respir Med. 2022;200:106863.
    PubMed     Abstract available

  67. SIRAJ RA, McKeever TM, Gibson JE, Bolton CE, et al
    Incidence of depression and antidepressant prescription in patients with COPD: A large UK population-based cohort study.
    Respir Med. 2022;196:106804.
    PubMed     Abstract available

  68. HARTMAN JE, Welling JBA, Klooster K, Carpaij OA, et al
    Survival in COPD patients treated with bronchoscopic lung volume reduction.
    Respir Med. 2022;196:106825.
    PubMed     Abstract available

  69. HESSE K, Bourke S, Steer J
    Heart failure in patients with COPD exacerbations: Looking below the tip of the iceberg.
    Respir Med. 2022;196:106800.
    PubMed     Abstract available

    April 2022
  70. CHIU YC, Chang WP, Tang GJ, Lan TY, et al
    Chronic obstructive pulmonary disease is associated with a higher risk of functional gastrointestinal disorders.
    Respir Med. 2022;197:106833.
    PubMed     Abstract available

  71. OBLING N, Backer V, Hurst JR, Bodtger U, et al
    Nasal and systemic inflammation in Chronic Obstructive Pulmonary Disease (COPD).
    Respir Med. 2022;195:106774.
    PubMed     Abstract available

  72. MACDONALD DM, Palzer EF, Abbasi A, Baldomero AK, et al
    Chronotropic index during 6-minute walk and acute respiratory events in COPDGene.
    Respir Med. 2022;194:106775.
    PubMed     Abstract available

    March 2022
  73. KORN S, Milger K, Skowasch D, Timmermann H, et al
    Corrigendum to "The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control" [Respir. Med. 195 (2022) 106793].
    Respir Med. 2022;196:106827.

  74. RILEY L, Lascano J
    Labelling Alpha-1 antitrypsin deficiency in the medical record - A call to action.
    Respir Med. 2022;193:106749.
    PubMed     Abstract available

  75. YOHANNES AM, Casaburi R, Dryden S, Hanania NA, et al
    Predictors of premature discontinuation and prevalence of dropouts from a pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease.
    Respir Med. 2022;193:106742.
    PubMed     Abstract available

  76. PHILLIPS TM, Moloney C, Sneath E, Beccaria G, et al
    Associated factors, assessment, management, and outcomes of patients who present to the emergency department for acute exacerbation of chronic obstructive pulmonary disease: A scoping review.
    Respir Med. 2022;193:106747.
    PubMed     Abstract available

    February 2022
  77. KORN S, Milger K, Skowasch D, Timmermann H, et al
    The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control.
    Respir Med. 2022;195:106793.
    PubMed     Abstract available

  78. BENDIEN SA, van Leeuwen MM, Lau HS, Ten Brinke A, et al
    Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands - An evaluation.
    Respir Med. 2022 Feb 23:106776. doi: 10.1016/j.rmed.2022.106776.
    PubMed     Abstract available

  79. AL-AHMAD M, Webb D
    A prospective study of switching asthma patients from a Fixed-Dose Combination (FDC) Inhaled Corticosteroid [ICS]/Long-Acting Beta Agonist [LABA] therapy delivered by Dry Powder Inhaler (DPI) to ICS/LABA delivered by pressurised Metered Dose Inhaler (
    Respir Med. 2022;194:106771.
    PubMed     Abstract available

  80. ABOZID H, Baxter CA, Hartl S, Braun E, et al
    Distribution of chronic cough phenotypes in the general population: A cross-sectional analysis of the LEAD cohort in Austria.
    Respir Med. 2022;192:106726.
    PubMed     Abstract available

  81. MAROTT JL, Colak Y, Ingebrigtsen TS, Vestbo J, et al
    Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population.
    Respir Med. 2022;192:106725.
    PubMed     Abstract available

    January 2022
  82. JI Z, Lopez-de-Andres A, Jimenez-Garcia R, Maestre-Miquel C, et al
    Mental health in patients with asthma: A population-based case-control study.
    Respir Med. 2022;193:106758.
    PubMed     Abstract available

  83. VRSALOVIC R, Korosec P, Stefanovic IM, Bidovec-Stojkovic U, et al
    Value of thymic stromal lymphopoietin as a biomarker in children with asthma.
    Respir Med. 2022;193:106757.
    PubMed     Abstract available

  84. METERSKY ML, Choate R, Aksamit TR, Conrad D, et al
    Stenotrophomonas maltophilia in patients with bronchiectasis: An analysis of the US bronchiectasis and NTM Research Registry.
    Respir Med. 2022;193:106746.
    PubMed     Abstract available

  85. TAKASAKA N, Hosaka Y, Fukuda T, Shinfuku K, et al
    Impact of emphysema on the prognosis of Mycobacterium avium complex pulmonary disease.
    Respir Med. 2022;192:106738.
    PubMed     Abstract available

  86. ELBORN JS, Blasi F, Haworth CS, Ballmann M, et al
    Bronchiectasis and inhaled tobramycin: A literature review.
    Respir Med. 2022;192:106728.
    PubMed     Abstract available

  87. BOURDIN A, Molinari N
    Non-optimal methodology questions indirect treatment comparison of dupilumab vs. other biologics in severe asthma.
    Respir Med. 2022;191:105999.

  88. BATEMAN ED, Khan AH, Xu Y, Guyot P, et al
    Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma".
    Respir Med. 2022;191:106088.

  89. MARTIN N, Papi A, Bratton DJ, Chan R, et al
    Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020].
    Respir Med. 2022;191:106065.

  90. BATEMAN ED, Khan AH, Xu Y, Guyot P, et al
    Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Respir Med. 2022;191:105991.
    PubMed     Abstract available

  91. SHEIKH D, Tripathi N, Chandler TR, Furmanek S, et al
    Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia.
    Respir Med. 2022;191:106714.
    PubMed     Abstract available

  92. BERGHAUS TM, Karschnia P, Haberl S, Schwaiblmair M, et al
    Disproportionate decline in admissions for exacerbated COPD during the COVID-19 pandemic.
    Respir Med. 2022;191:106120.

  93. MIR T, Uddin M, Khalil A, Lohia P, et al
    Mortality outcomes associated with invasive aspergillosis among acute exacerbation of chronic obstructive pulmonary disease patient population.
    Respir Med. 2022;191:106720.
    PubMed     Abstract available

  94. OBLING N, Rangelov B, Backer V, Hurst JR, et al
    Upper airway symptoms and Small Airways Disease in Chronic Obstructive Pulmonary Disease, COPD.
    Respir Med. 2022;191:106710.
    PubMed     Abstract available

  95. JALASTO J, Lassmann-Klee P, Schyllert C, Luukkonen R, et al
    Occupation, socioeconomic status and chronic obstructive respiratory diseases - The EpiLung study in Finland, Estonia and Sweden.
    Respir Med. 2022;191:106403.
    PubMed     Abstract available

  96. OBI ON, Judson MA, Birring SS, Maier LA, et al
    Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI).
    Respir Med. 2022;191:106436.
    PubMed     Abstract available

  97. BATEMAN ED, Khan AH, Xu Y, Guyot P, et al
    Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020).
    Respir Med. 2022;191:106106.

    December 2021
  98. TERPSTRA LC, Altenburg J, Mohamed Hoesein FA, Bronsveld I, et al
    The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial.
    Respir Med. 2021;192:106718.
    PubMed     Abstract available

  99. MONTEIRO C, Maricoto T, Prazeres F, Augusto Simoes P, et al
    Determining factors associated with inhaled therapy adherence on asthma and COPD: A systematic review and meta-analysis of the global literature.
    Respir Med. 2021;191:106724.
    PubMed     Abstract available

  100. WILGUS ML, Abtin F, Markovic D, Tashkin DP, et al
    Panlobular emphysema is associated with COPD disease severity: A study of emphysema subtype by computed tomography.
    Respir Med. 2021;192:106717.
    PubMed     Abstract available

  101. BARTOLI ML, Latorre M, Vagaggini B, Nieri D, et al
    Are sputum eosinophils associated with a different phenotype in COPD patients? A retrospective study.
    Respir Med. 2021;190:106672.
    PubMed     Abstract available

  102. PENG J, Wu F, Tian H, Yang H, et al
    Clinical characteristics of and risk factors for small airway dysfunction detected by impulse oscillometry.
    Respir Med. 2021;190:106681.
    PubMed     Abstract available

  103. MONGIARDO MA, Robinson SA, Finer EB, Cruz Rivera PN, et al
    The Effect of a web-based physical activity intervention on COPD knowledge: A secondary cohort study.
    Respir Med. 2021;190:106677.
    PubMed     Abstract available

  104. LEE CT, Chien JY, Hsu MJ, Wu HD, et al
    Inspiratory muscle activation during inspiratory muscle training in patients with COPD.
    Respir Med. 2021;190:106676.
    PubMed     Abstract available

  105. YAMAMOTO A, Nakamoto H, Yamaguchi T, Sakai H, et al
    Validity of a novel respiratory rate monitor comprising stretchable strain sensors during a 6-min walking test in patients with chronic pulmonary obstructive disease.
    Respir Med. 2021;190:106675.
    PubMed     Abstract available

  106. CAILLE P, Alexandre F, Molinier V, Heraud N, et al
    The role of personality traits in inpatient pulmonary rehabilitation response in patients with chronic obstructive pulmonary disease.
    Respir Med. 2021;190:106680.
    PubMed     Abstract available

  107. AL CHIKHANIE Y, Bailly S, Amroussia I, Veale D, et al
    Trajectories of COPD patients' response to repeated pulmonary rehabilitation programs.
    Respir Med. 2021;190:106678.
    PubMed     Abstract available

  108. IRINA BP, Steluta MM, Emanuela T, Diana M, et al
    Respiratory muscle training program supplemented by a cell-phone application in COPD patients with severe airflow limitation.
    Respir Med. 2021;190:106679.
    PubMed     Abstract available

    November 2021
  109. FAN Q, Ong ASE, Koh MS, Doshi K, et al
    The mediating role of trust in physician and self-efficacy in understanding medication adherence in severe asthma.
    Respir Med. 2021;190:106673.
    PubMed     Abstract available

  110. JEONG JS, Kim JS, You YS, Yeom SW, et al
    COPD is a risk factor for COVID-19, but does not confer increased severity of the disease.
    Respir Med. 2021;189:106640.
    PubMed     Abstract available

  111. SUISSA S, Dell'Aniello S, Ernst P
    Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety.
    Respir Med. 2021;189:106645.
    PubMed     Abstract available

  112. PALM A, Ekstrom M
    Hypoxemia severity and survival in ILD and COPD on long-term oxygen therapy - The population-based DISCOVERY study.
    Respir Med. 2021;189:106659.
    PubMed     Abstract available

  113. DE BISSCHOP C, Caron F, Ingrand P, Bretonneau Q, et al
    Does branched-chain amino acid supplementation improve pulmonary rehabilitation effect in COPD?
    Respir Med. 2021;189:106642.
    PubMed     Abstract available

  114. KARIM A, Muhammad T, Ustrana S, Qaisar R, et al
    Intestinal permeability marker zonulin as a predictor of sarcopenia in chronic obstructive pulmonary disease.
    Respir Med. 2021;189:106662.
    PubMed     Abstract available

  115. OIE MR, Sue-Chu M, Helvik AS, Steinsvag SK, et al
    Rhinosinusitis without nasal polyps is associated with poorer health-related quality of life in COPD.
    Respir Med. 2021;189:106661.
    PubMed     Abstract available

  116. KUNUTSOR SK, Jae SY, Makikallio TH, Kurl S, et al
    High fitness levels offset the increased risk of chronic obstructive pulmonary disease due to low socioeconomic status: A cohort study.
    Respir Med. 2021;189:106647.
    PubMed     Abstract available

  117. AL-MOAMARY MS, Kokturk N, Idrees MM, Sen E, et al
    Unmet need in the management of chronic obstructive pulmonary disease in the Middle East and Africa region: An expert panel consensus.
    Respir Med. 2021;189:106641.
    PubMed     Abstract available

  118. IWAKURA M, Wakasa M, Okura K, Kawagoshi A, et al
    Functionally relevant threshold of inspiratory muscle strength in patients with chronic obstructive pulmonary disease.
    Respir Med. 2021;188:106625.
    PubMed     Abstract available

  119. AGGARWAL R, Lam AC, Huang J, Hueniken K, et al
    Stratification and management of patients ineligible for lung cancer screening.
    Respir Med. 2021;188:106610.
    PubMed     Abstract available

  120. ZAIGHAM S, Zhou X, Molin M, Sjolander A, et al
    Importance of type and degree of IgE sensitisation for defining fractional exhaled nitric oxide reference values.
    Respir Med. 2021;188:106621.
    PubMed     Abstract available

  121. HARTMAN JE, Conway F, Degano B, Augustijn SWS, et al
    Rate of lung function decline slows in the 3 years after targeted lung denervation in COPD.
    Respir Med. 2021;188:106604.

  122. KEMP R, Pustulka I, Boerner G, Smela B, et al
    Relationship between FEV1 decline and mortality in patients with bronchiolitis obliterans syndrome-a systematic literature review.
    Respir Med. 2021;188:106608.
    PubMed     Abstract available

    October 2021
  123. CZIRA A, Turner M, Martin A, Hinds D, et al
    A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma.
    Respir Med. 2021;191:106670.
    PubMed     Abstract available

  124. ROGLIANI P, Ritondo BL, Puxeddu E, Cazzola M, et al
    Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review.
    Respir Med. 2021;189:106639.
    PubMed     Abstract available

  125. CHEN J, Weldemichael L, Zeng S, Giang B, et al
    Actigraphy informs distinct patient-centered outcomes in Pre-COPD.
    Respir Med. 2021;187:106543.
    PubMed     Abstract available

  126. RODRIGUEZ-GARCIA C, Blanco-Aparicio M, Nieto-Fontarigo JJ, Blanco-Cid N, et al
    Efficacy of mepolizumab in usual clinical practice and characteristics of responders.
    Respir Med. 2021;187:106595.
    PubMed     Abstract available

  127. AGUSTI A, Barnes N, Cruz AA, Gibson PG, et al
    Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.
    Respir Med. 2021;187:106572.
    PubMed     Abstract available

  128. HOSKING L, Yeo A, Hoffman J, Chiano M, et al
    Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation.
    Respir Med. 2021;187:106573.
    PubMed     Abstract available

  129. WAN ES, Goldstein RL, Garshick E, DeMeo DL, et al
    Molecular markers of aging, exercise capacity, & physical activity in COPD.
    Respir Med. 2021;187:106576.
    PubMed     Abstract available

  130. RIIKONEN R, Korppi M, Tormanen S, Koponen P, et al
    Risk factors for irreversible airway obstruction after infant bronchiolitis.
    Respir Med. 2021;187:106545.
    PubMed     Abstract available

    September 2021
  131. KAPUR N, Stroil-Salama E, Morgan L, Yerkovich S, et al
    Factors associated with "Frequent Exacerbator" phenotype in children with bronchiectasis: The first report on children from the Australian Bronchiectasis Registry.
    Respir Med. 2021;188:106627.
    PubMed     Abstract available

  132. OLIVEIRA A, Quach S, Alsubheen S, Dasouki S, et al
    Rapid access rehabilitation after exacerbations of COPD - A qualitative study.
    Respir Med. 2021;186:106532.
    PubMed     Abstract available

  133. LEO F, Bannehr M, Valenta S, Lippeck M, et al
    Impact of a computerized physician order entry (CPOE)-based antibiotic stewardship intervention on the treatment duration for pneumonia and COPD exacerbations.
    Respir Med. 2021;186:106546.
    PubMed     Abstract available

  134. GAZOURIAN L, Regis SM, Pagura EJ, Price LL, et al
    Qualitative coronary artery calcification scores and risk of all cause, COPD and pneumonia hospital admission in a large CT lung cancer screening cohort.
    Respir Med. 2021;186:106540.
    PubMed     Abstract available

  135. NIKOLAOU V, Massaro S, Garn W, Fakhimi M, et al
    The cardiovascular phenotype of Chronic Obstructive Pulmonary Disease (COPD): Applying machine learning to the prediction of cardiovascular comorbidities.
    Respir Med. 2021;186:106528.
    PubMed     Abstract available

  136. CAMAC ER, Voelker H, Criner GJ
    Impact of COPD exacerbations leading to hospitalization on general and disease-specific quality of life.
    Respir Med. 2021;186:106526.
    PubMed     Abstract available

  137. LINDBERG A, Lindberg L, Sawalha S, Nilsson U, et al
    Large underreporting of COPD as cause of death-results from a population-based cohort study.
    Respir Med. 2021;186:106518.
    PubMed     Abstract available

    August 2021
  138. VITACCA M, Ambrosino N, Belli S, Vigna M, et al
    The severity of acute exacerbations of COPD and the effectiveness of pulmonary rehabilitation.
    Respir Med. 2021;184:106465.
    PubMed     Abstract available

  139. GILLIAM EA, Kilgore KL, Liu Y, Bernier L, et al
    Managing the experience of breathlessness with Tai Chi: A qualitative analysis from a randomized controlled trial in COPD.
    Respir Med. 2021;184:106463.
    PubMed     Abstract available

  140. GUO C, Yu T, Chang LY, Bo Y, et al
    Mortality risk attributable to classification of chronic obstructive pulmonary disease and reduced lung function: A 21-year longitudinal cohort study.
    Respir Med. 2021;184:106471.
    PubMed     Abstract available

  141. METERAN H, Thomsen SF, Miller MR, Hjelmborg J, et al
    Impact of the spirometric definition on comorbidities in chronic obstructive pulmonary disease.
    Respir Med. 2021;184:106399.
    PubMed     Abstract available

  142. TAKEI N, Suzuki M, Tanabe N, Oguma A, et al
    Combined assessment of pulmonary arterial enlargement and coronary calcification predicts the prognosis of patients with chronic obstructive pulmonary disease.
    Respir Med. 2021;185:106520.
    PubMed     Abstract available

  143. CASTELLO-SIMOES V, Kabbach EZ, Schafauser NS, Camargo PF, et al
    Brain-heart autonomic axis across different clinical status and severity of chronic obstructive pulmonary disease.
    Respir Med. 2021;185:106511.
    PubMed     Abstract available

  144. CORLATEANU A, Plahotniuc A, Corlateanu O, Botnaru V, et al
    Multidimensional indices in the assessment of chronic obstructive pulmonary disease.
    Respir Med. 2021;185:106519.
    PubMed     Abstract available

  145. MARTINEZ FJ, Rabe KF, Ferguson GT, Wedzicha JA, et al
    Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial.
    Respir Med. 2021;185:106509.
    PubMed     Abstract available

  146. KELLERER C, Kahnert K, Trudzinski FC, Lutter J, et al
    COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort.
    Respir Med. 2021;185:106461.
    PubMed     Abstract available

  147. PATHAK JL, Yan Y, Zhang Q, Wang L, et al
    The role of oral microbiome in respiratory health and diseases.
    Respir Med. 2021;185:106475.
    PubMed     Abstract available

  148. ANDRIANOPOULOS V, Gloeckl R, Schneeberger T, Jarosch I, et al
    Benefits of pulmonary rehabilitation in COPD patients with mild cognitive impairment - A pilot study.
    Respir Med. 2021;185:106478.
    PubMed     Abstract available

    June 2021
  149. SHE W, Jia S, Hua Y, Feng X, et al
    The effect of nitrogen dioxide and atmospheric pressure on hospitalization risk for chronic obstructive pulmonary disease in Guangzhou, China.
    Respir Med. 2021;182:106424.
    PubMed     Abstract available

  150. CANTOR JO, Ma S, Liu X, Campos MA, et al
    A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy.
    Respir Med. 2021;182:106402.
    PubMed     Abstract available

  151. MARTH K, Renner A, Pohl W
    TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD.
    Respir Med. 2021;182:106398.
    PubMed     Abstract available

  152. KRAEN M, Frantz S, Nihlen U, Engstrom G, et al
    Fibroblast growth factor 23 is an independent marker of COPD and is associated with impairment of pulmonary function and diffusing capacity.
    Respir Med. 2021;182:106404.
    PubMed     Abstract available

  153. KIM C, Ko Y, Lee JS, Rhee CK, et al
    Predicting long-term mortality with two different criteria of exercise-induced desaturation in COPD.
    Respir Med. 2021;182:106393.
    PubMed     Abstract available

  154. AMADO CA, Munoz P, Garcia-Unzueta M, Aguero J, et al
    High parathyroid hormone predicts exacerbations in COPD patients with hypovitaminosis D.
    Respir Med. 2021;182:106416.
    PubMed     Abstract available

  155. AL-QEREM WA, Jarab AS
    Applicability of GLI 2012 spirometry equation among preschool aged Jordanian.
    Respir Med. 2021;182:106397.
    PubMed     Abstract available

    May 2021
  156. PUDDU PE, Menotti A, Kromhout D, Kafatos A, et al
    Chronic bronchitis in the 50-year follow-up of the European cohorts of the Seven Countries Study: prevalence, mortality and association with cardiovascular diseases.
    Respir Med. 2021;181:106385.
    PubMed     Abstract available

  157. VINCKEN S, Sylvia V, Daniel S, Thomas E, et al
    The role of FeNO in stable COPD patients with eosinophilic airway inflammation.
    Respir Med. 2021;181:106377.

  158. CORDOVA-RIVERA L, Gardiner PA, Gibson PG, Winkler EAH, et al
    Sedentary time in people with obstructive airway diseases.
    Respir Med. 2021;181:106367.
    PubMed     Abstract available

  159. HEUBEL AD, Kabbach EZ, Schafauser NS, Phillips SA, et al
    Noninvasive ventilation acutely improves endothelial function in exacerbated COPD patients.
    Respir Med. 2021;181:106389.
    PubMed     Abstract available

    April 2021
  160. PINI L, Giordani J, Gardini G, Concoreggi C, et al
    Emergency department admission and hospitalization for COPD exacerbation and particulate matter short-term exposure in Brescia, a highly polluted town in northern Italy.
    Respir Med. 2021;179:106334.
    PubMed     Abstract available

  161. YANGUI F, Touil A, Antit S, Zakhama L, et al
    COPD prevalence in smokers with stable ischemic heart disease: A cross-sectional study in Tunisia.
    Respir Med. 2021;179:106335.
    PubMed     Abstract available

  162. VERBERKT CA, van den Beuken-van Everdingen MHJ, Dirksen CD, Schols JMGA, et al
    Cost-effectiveness of sustained-release morphine for refractory breathlessness in COPD: A randomized clinical trial.
    Respir Med. 2021;179:106330.
    PubMed     Abstract available

  163. TIOTIU A, Ioan I, Poussel M, Schweitzer C, et al
    Comparative analysis between available challenge tests in the hyperventilation syndrome.
    Respir Med. 2021;179:106329.
    PubMed     Abstract available

  164. ARMSTRONG M, Hume E, McNeillie L, Chambers F, et al
    Behavioural modification interventions alongside pulmonary rehabilitation improve COPD patients' experiences of physical activity.
    Respir Med. 2021;180:106353.
    PubMed     Abstract available

  165. LAMMI MR, Ghonim MA, Johnson J, D'Aquin J, et al
    Acute effect of inhaled iloprost on exercise dynamic hyperinflation in COPD patients: A randomized crossover study.
    Respir Med. 2021;180:106354.
    PubMed     Abstract available

    March 2021
  166. TURAN PA, Turan O, Guldaval F, Anar C, et al
    Transitions between COPD groups: A cross-sectional study in Turkey.
    Respir Med. 2021;178:106310.
    PubMed     Abstract available

    January 2021
  167. ZELL-BARAN LM, Krefft SD, Moore CM, Wolff J, et al
    Multiple breath washout: A noninvasive tool for identifying lung disease in symptomatic military deployers.
    Respir Med. 2021;176:106281.
    PubMed     Abstract available

  168. OLIVEIRA CC, Annoni R, Lee AL, McGinley J, et al
    Falls prevalence and risk factors in people with chronic obstructive pulmonary disease: A systematic review.
    Respir Med. 2021;176:106284.
    PubMed     Abstract available

  169. LOPEZ-PINTOR E, Grau J, Gonzalez I, Bernal-Soriano MC, et al
    Impact of patients' perception of COPD and treatment on adherence and health-related quality of life in real-world: Study in 53 community pharmacies.
    Respir Med. 2021;176:106280.
    PubMed     Abstract available

  170. BAHA A, Kokturk N
    Physician's attitude against COPD guidelines and the choice of first-line treatment for COPD.
    Respir Med. 2021;176:106273.
    PubMed     Abstract available

  171. BJERRUM AS, Skjold T, Schmid JM
    Oral corticosteroid sparing effects of anti-IL5/ anti-IL5 receptor treatment after 2 years of treatment.
    Respir Med. 2021;176:106260.
    PubMed     Abstract available

  172. FRANCE G, Orme MW, Greening NJ, Steiner MC, et al
    Cognitive function following pulmonary rehabilitation and post-discharge recovery from exacerbation in people with COPD.
    Respir Med. 2021;176:106249.
    PubMed     Abstract available

  173. KEOGH E, Mark Williams E
    Managing malnutrition in COPD: A review.
    Respir Med. 2021;176:106248.
    PubMed     Abstract available

  174. ZAIGHAM S, Dencker M, Karlsson MK, Thorsson O, et al
    Lung function is associated with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in school-aged children.
    Respir Med. 2021;176:106235.
    PubMed     Abstract available

  175. KOHLBRENNER D, Clarenbach CF, Thiel S, Roeder M, et al
    A few more steps lead to improvements in endothelial function in severe and very severe COPD.
    Respir Med. 2021;176:106246.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Obstructive Lung Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.